ABSTRACT Introduction Polatuzumab vedotin (Pola) is an antibody‐drug conjugate approved for the treatment of diffuse large B‐cell lymphoma (DLBCL). Several reports suggest that the tumor microenvironment influences the outcome of DLBCL treatments; with Pola, however, the link between tumor microenvironment and treatment outcome remains unclear ...
Mayu Tomita +9 more
wiley +1 more source
ABSTRACT Transitioning between mental health services is a vulnerable process that can challenge treatment outcomes. This study explores the experience of moving from Child and Adolescent Mental Health Services (CAMHS) to Adult Mental Health Services (AMHS) from the perspective of young people with anorexia nervosa.
Sofie Harboe +5 more
wiley +1 more source
Factors that influence acute malnutrition detection and treatment by community health promoters in Samburu and Turkana counties, Kenya: A mixed methods study. [PDF]
Ng'ang'a MN +10 more
europepmc +1 more source
Real-World Outcomes of Polatuzumab Vedotin Plus R-CHP Versus R-CHOP-Based Regimens in Japanese Patients With Untreated Diffuse Large B-Cell Lymphoma. [PDF]
Hotta M +8 more
europepmc +1 more source
Changes in interictal cerebral blood flow observed in migraine patients who respond to anti-calcitonin gene-related peptide therapy. [PDF]
Shimoda M +5 more
europepmc +1 more source
γ-Cyclodextrin/Genistein Inclusion Complex Catalyzes GPx4-Mediated Reduction of Organic/Inorganic Peroxides: Based on SERS and In Silico Research. [PDF]
Zhang M +5 more
europepmc +1 more source
Characterizing choroid plexus cyst burden across the Alzheimer's disease continuum. [PDF]
Li K +9 more
europepmc +1 more source
Aberrant adenosine A<sub>2A</sub> receptor signaling in the choroid plexus drives CSF hypersecretion and ventriculomegaly in hydrocephalus. [PDF]
Zheng W +15 more
europepmc +1 more source
Reclassifying hospital energy demand toward industry-like requirements for hygienic and resilient indoor environments. [PDF]
Lakjiri S, Ouassaid M.
europepmc +1 more source

